Nucletron gains FDA OK for "time-saving" brachytherapy
This article was originally published in Clinica
Executive Summary
The US FDA has cleared a device designed to allow doctors greater accuracy during breast brachytherapy procedures. The Kuske breast template, developed by Nucletron, also enables patients with breast cancer to be treated in four to five days, rather than the typical five to seven weeks that is required with external beam radiation, the company says.